The jury made this award on the basis that the company, Wyeth, failed to warn about the risks of the drug and took only minutes to come to their decision.
On 15 March, 2010 Pfizer announced that they have stopped a phase-III trial of their monoclonal antibody Figitumumab and two trials of Sunitinib in breast cancer after they failed to show significant improvement in survival rates.
Dr. Scott Reuben, a former member of Pfizer’s speakers’ bureau, has agreed to plead guilty to faking dozens of research studies that were published in medical journals.